SNTB2

SNTB2 is a PDZ domain-containing syntrophin that acts as a membrane-associated scaffold/adaptor, originally identified as a 59-kDa component of the dystrophin-associated protein complex of the muscle membrane cytoskeleton (PMID:8183929). Through its PDZ domain it engages the C-terminal PDZ ligands of specific membrane receptors: it binds the α1D-adrenergic receptor (ADRA1D) to ensure receptor plasma membrane localization and G-protein coupling, with selectivity for ADRA1D over other PDZ-ligand GPCRs tested (PMID:26617989), and it binds the C-terminus of adiponectin receptor 1 (AdipoR1), although this interaction is dispensable for AdipoR1 signaling and stability in liver (PMID:23860432). SNTB2 partners with utrophin in a complex that restrains lipid droplet expansion during adipogenesis, and its stability depends on utrophin (PMID:30014220). In vivo, SNTB2 regulates adipocyte size, caveolin-1 levels, and postprandial lipid and glucose metabolism (PMID:30990585), and it shapes hepatic SR-BI abundance indirectly by limiting ERK/MAPK activity, an effect that requires combined loss of SNTB2 and α-syntrophin (PMID:25625330).

1. 1994 Medium

   Established the molecular identity of SNTB2 by showing it is a distinct syntrophin isoform belonging to the dystrophin-associated protein complex of the muscle membrane cytoskeleton.

   Evidence cDNA cloning, peptide sequencing of purified DAP complex, and chromosomal mapping

   PMID:8183929

   Open questions at the time

   • Does not define the binding partners engaged by its PDZ domain
   • No functional role assigned beyond complex membership
2. 2013 Medium

   Tested whether SNTB2's PDZ interaction with AdipoR1 is functionally required, addressing whether SNTB2 acts as a signaling adaptor for adiponectin signaling.

   Evidence Yeast two-hybrid liver library screen, PDZ-domain array, and knockout mouse readouts of AMPK/p38 phosphorylation

   PMID:23860432

   Open questions at the time

   • The biological consequence of the AdipoR1–SNTB2 interaction outside liver is undefined
   • No structural basis for the PDZ-ligand binding shown
3. 2013 Low

   Linked SNTB2 expression to a cellular phenotype by showing knockdown sensitizes lung cancer cells to radiation, implicating it in radioresistance.

   Evidence Microarray profiling, siRNA knockdown, and clonogenic survival assays in lung cancer lines

   PMID:24465237

   Open questions at the time

   • No mechanistic pathway connecting SNTB2 to the DNA damage or survival response
   • Single siRNA approach without rescue
4. 2015 Medium

   Demonstrated PDZ-ligand-specific recruitment of the α1D-adrenergic receptor by SNTB2, establishing a defined receptor-scaffolding function controlling receptor membrane localization and coupling.

   Evidence TAP/MS proteomics, biochemical binding assays, and dynamic mass redistribution analysis with a panel of 22 control GPCRs

   PMID:26617989

   Open questions at the time

   • Whether other syntrophin-binding receptors exist in vivo is unresolved
   • No structural model of the ADRA1D–SNTB2 PDZ interface
5. 2015 Medium

   Revealed an indirect role for SNTB2 in hepatic SR-BI stability via ERK control, distinguishing combined syntrophin loss from single-gene knockdown.

   Evidence α/β2-syntrophin double-knockout mice, ERK inhibitor treatment, and hepatocyte siRNA knockdown with Western blot

   PMID:25625330

   Open questions at the time

   • The molecular link between syntrophin loss and elevated ERK activity is not defined
   • Functional redundancy with α-syntrophin obscures the SNTB2-specific contribution
6. 2018 Medium

   Placed SNTB2 in a utrophin-dependent pathway restraining lipid droplet growth and identified a specific modulation of insulin's antilipolytic arm in adipocytes.

   Evidence Reciprocal Co-IP, siRNA knockdown, lipid droplet sizing, lipolysis assays, and phospho-Akt Western blot

   PMID:30014220

   Open questions at the time

   • The mechanism by which the utrophin–SNTB2 complex limits lipid droplet expansion is unknown
   • How SNTB2 selectively affects antilipolytic insulin signaling without altering Akt is unresolved
7. 2019 Medium

   Defined SNTB2 as an in vivo regulator of adipocyte size, caveolin-1 expression, and postprandial lipid/glucose metabolism under dietary challenge.

   Evidence SNTB2 knockout mice on high-fat diet with histology, Western blot, and serum metabolite measurements

   PMID:30990585

   Open questions at the time

   • The direct molecular target linking SNTB2 to caveolin-1 levels is not identified
   • Whether the metabolic phenotype derives from adipocyte-autonomous SNTB2 function is untested

• The unifying biochemical mechanism by which SNTB2's PDZ-mediated scaffolding controls receptor signaling, lipid droplet dynamics, and ERK activity across tissues remains unresolved.
• No structural data on SNTB2 PDZ-ligand complexes
• No single signaling pathway unifies its adrenergic, adiponectin, and metabolic roles
• Tissue-specific contributions versus syntrophin redundancy not separated